TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00825734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
Study: NCT04112875

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: Handled powdered supplement to be mixed with water, has orange flavor for oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
Study: NCT02242799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Dolutegravir 50mg once daily will be given either alone or in combination, as specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Dolutegravir 50mg once daily will be given either alone or in combination, as specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Dolutegravir 50mg once daily will be given either alone or in combination, as specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
Study: NCT01002911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin, Bacitracin, Cefalexin
Description: Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
Study: NCT02380638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.
Study: NCT01315197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
Study: NCT03503162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Study: NCT02513979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin type II receptor antagonists
Description: Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
Study: NCT02668796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Tablets 10 mcg (Glenmark)
Description: apply using the given applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
Description: apply using the given applicator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Description: apply using the given applicator
Study: NCT03692221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSC Treatment group 2 (high dose)
Description: Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Control (no treatment)
Description: Comparative analysis of psychometric and morphometric based data
Study: NCT02250183

Intervention type: DEVICE
Group type: OTHER
Intervention: MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY
Description: MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.

Intervention type: DEVICE
Group type: OTHER
Intervention: Santyl
Description: SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
Study: NCT00543166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dehydroepiandrosterone
Description: 50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
Study: NCT01870414

Intervention type: OTHER
Group type: OTHER
Intervention: cryotherapy by immersion
Description: the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
Study: NCT02324088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study: NCT02683356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided PCI
Description: Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
Study: NCT03306693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional skills
Description: 2-hour 3 group sessions

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation and talking group
Description: 2-hour 3 group sessions
Study: NCT02840071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Description: Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
Study: NCT01924806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WoundWand™ Debridement Device
Description: Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sharp debridement
Description: Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
Study: NCT03951935

Intervention type: OTHER
Intervention: Oswestry Disability Index (ODI) questionnaire
Description: Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
Study: NCT04456868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment
Study: NCT03951935

Intervention type: OTHER
Intervention: Oswestry Disability Index (ODI) questionnaire
Description: Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: self-paced walking test (SPWT)
Description: walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: self-paced walking test (SPWT)
Description: walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
Study: NCT01026714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: assessment of flurbiprofen plasmatic and capillary rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen, rifampicin
Description: assessment of flurbiprofen plasmatic and capillary rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen + fluconazole
Description: assessment of flurbiprofen plasmatic and capillary rates
Study: NCT04432064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TI-NDBS
Description: In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TI-NDBS
Description: In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TI-NDBS
Description: This is the control condition in which participants will receive sham stimulation for 60 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TI-NDBS
Description: This is the control condition in which participants will receive sham stimulation for 60 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
Study: NCT02327273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04456868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position emission tomography
Description: Position emission tomography will be done for

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position emission tomography
Description: Position emission tomography will be done for

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position emission tomography
Description: Position emission tomography will be done for
Study: NCT00887523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: radiation in prone position
Description: radiation in prone position

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: radiation in supine position
Description: radiation in supine position
Study: NCT04010526

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: local co-administration of autologous ADIpose
Description: local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
Study: NCT02076503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MR 18f-FACBC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histology (gold standard)
Description: histopathological classification of co-located dissected lymph nodes
Study: NCT02210247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Study: NCT00006398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04433715

Intervention type: DIAGNOSTIC_TEST
Intervention: ICIQ-SF
Description: All participants completed ICIQ-SF,

Intervention type: DIAGNOSTIC_TEST
Intervention: ICIQ-SF
Description: All participants completed ICIQ-SF,
Study: NCT03291899

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
Study: NCT02937051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
Study: NCT00658983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Enriched Gel
Description: Treatment with Autologous Platelet Enriched Gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metalloproteinase Inhibitor
Description: Treatment with Metalloproteinase Inhibitor (Promogran)
Study: NCT04433715

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6
Description: All participants completed UDI-6

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6
Description: All participants completed UDI-6

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7
Description: All participants completed IIQ-7

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7
Description: All participants completed IIQ-7
Study: NCT03986983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
Study: NCT04091919

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D- Transthoracic Echocardiography (TTE)
Description: 2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D- Transthoracic Echocardiography (TTE)
Description: 2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging